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Abstract:  
Background: Studies have been shown that the prevalence of metabolic syndrome changes among 
different ethnic and sex groups. Objective: We determined age related prevalence of metabolic syndrome 
among Fars ethnic women. Study design: Health center based study. Setting: Metabolic Disorders 
Research Center in Gorgan. Participants: 160 Fars adult women. Sampling: randomized sampling method. 
Results: The most age distribution was in ages from 35 to 40 years (50%). There were significant 
differences between the mean value of waist circumferences, fasting blood glucose, body mass index and 
triglyceride among subjects with and without metabolic syndrome in age groups 20-24 and 25-29 years 
old (P<0.05). HDL-cholesterol and LDL-cholesterol levels were significantly decreased and increased in 
these age groups, respectively (P<0.05). There were also significant increases in fasting blood glucose and 
triglyceride levels  among subjects with and without metabolic syndrome in age groups 30-34 and 35-40 
years old (P<0.05). There were decreased HDL-cholesterol in age group 30-34 years old (P<0.05). There 
were significant differences in the prevalence of metabolic syndrome in age groups 20-24 and 30-34 
years old (P<0.05). 
Conclusion: High waist circumference, Fasting Glucose and triglyceride, and low HDL cholesterol are more 
effective among subjects with metabolic syndrome and, in the presence of obesity may elevate the risk of 
coronary heart disease. The increasing number of overweight and obese subjects in our study makes 
certain that metabolic syndrome begins from young age and will continue as age progresses. It seems that 
women require altering their life style to prevent cardiovascular complications. 
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Introduction:  
he prevalence of the metabolic syndrome increases whole 
around the world. The metabolic syndrome is described by 
the clustering of hypertension, dyslipidaemia, central 
obesity, insulin resistance and high fasting plasma glucose[1]. In 
1923, metabolic syndrome was explained for the first time by 
Kyln[2].Gerald Reaven re-exhibited the concept of metabolic 
syndrome in 1988. He has been shown that metabolic syndrome is 
the clustering of hypertension, glucose intolerance; high 
triglycerides and low high density lipoprotein (HDL) 
concentration[3].Studies have been shown that the prevalence of 
metabolic syndrome changes among different ethnic groups[4-6]. 
The genetically differences, nutritional regiment, physical exercise, 
age and gender may affect the prevalence of metabolic syndrome 
and its components[7]. Many studies have indicated that the 
prevalence of metabolic syndrome changes worldwide 8-24% and 
7-46.5% among men and women, respectively[8-11]. The main 
causes of death among women are cardiovascular disease[12]. Many 
epidemiological studies have indicated the importance of the 
metabolic syndrome[13-15]. It has been shown that the metabolic 
syndrome causes health problem 
in developed and developing 
countries. The prevalence of 
metabolic syndrome in Europe 
and European Americans vary 
nearly 20%-30% in men and 
women [4, 7, 9 , 16-17]. It has been also 
revealed that the prevalence of 
metabolic syndrome is elevating 
in Asian countries[18]. It was 
reported that the prevalence of 
metabolic syndrome is the similar 
for men (24%) and women 
(23.7%) in the US, but there was 
an ethnic differences in the 
prevalence of metabolic 
syndrome[9].There are a few 
studies on the prevalence of the 
metabolic syndrome among adult 
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people. It has been indicated that the prevalence of the metabolic 
syndrome among 15 (in Japan), 12-19 (in the United States), 10-18 
(in Mexico), 10-19 (in Iran) [19-22] and 12-19 (US black) years old 
were 1%, 6.4%, 6.5%, 10% and 4%, respectively[23]. In present 
study, we determined age related prevalence of the metabolic 
syndrome among Fars ethnic women in this area (Gorgan, North 
East of Caspian Sea). 
 
Materials and methods: 
This present study was carried out in the Metabolic Disorders 
Research Center in Gorgan. 160 Fars adult females were took part 
(Women who speak only Persian language) that was directed to the 
Health Centers in Gorgan. Demographic data is collected by a 
questionnaire. Women with hormone replacement therapy, taking 
anti-diabetes and anti-hypertensive anti-lipidemic agents and 
active smokers were excluded. A blood sample was collected after 
8-12-hours fasting. Fasting blood glucose, triglycerides, total 
cholesterol, LDL-cholesterol and HDL-cholesterol levels were 
determined in serum of all subjects. Commercial kits and 
spectrophotometer techniques (Model JENWAY 6105 UV / VIS) 
were used to assess these biochemical parameters in the Metabolic 
Disorders Research Center. Metabolic syndrome among women 
was considered if any of subjects had 3 or more of the following 
ATP III Criteria [24]:  
 
1. Serum glucose level higher than 110 mg/dl. 
2. Low HDL-cholesterol lower than 50 mg/dl. 
3. Serum triglycerides level higher than 150 mg/dl. 
4. Systolic Blood Pressure (SBP) higher than 130 mmHg and/or 
Diastolic Blood Pressure (DBP) higher than 85 mmHg 
(Hypertension). 
5. Waist Circumference higher than 88 cm (Abdominal obesity). 
6.  
Weight was measured with minimal clothed, using digital scales. 
Height was measured with tape meter when the shoulder was in a 
normal position. Calculation of body mass index (BMI) was done 
when weight in kilograms divided by height in meters squared.  
BMI with 25.0-29.9 Kg/m2 were arranged as overweight. Subjects 
with a BMI  greater than 30 Kg/m2 and 45 Kg/m2 were specified as 
obese and very obese, respectively[25]. Abdominal obesity was 
assessed at the point halfway between the lower border of ribs and 
the iliac crest in a horizontal plane[26]. Blood pressure was 
determined in sitting position from the right hand. The results were 
reported in percentages and mean value. SPSS- 16 version software 
was used to analyze the data. Independent student t test was used 
to evaluate the results. P- Value lower than 0.05 was considered 
statistical significant. 
 
Results: 
160 Fars females were included in this study. The mean age of 
women was 53.65±9.50 years (the age range was 20-40 years old). 
The mean waist circumferences, fasting blood glucose, triglyceride, 
HDL-cholesterol, LDL-cholesterol 
levels, systolic blood pressure, 
diastolic blood pressure and body 
mass index were shown in table 1 
according to age distribution 
among Fars ethnic group. There 
were no significant differences 
between all parameters in 
different age groups.  The mean 
waist circumferences increased 
from age 25 to 40 years old. The 
mean HDL-cholesterol decreased 
in all age groups.  Table 2 shows 
distribution of metabolic 
syndrome components among 
subjects with and without 
metabolic syndrome according to 
age group. The most age 
distribution was in ages from 35 
to 40 years (50%). There were 
significant differences between 
the mean value of waist 
circumferences, fasting blood 
glucose, body mass index and 
triglyceride among subjects with 
and without metabolic syndrome 
in age groups 20-24 and 25-29 
years old (P<0.05). The mean 
HDL-cholesterol and LDL-
cholesterol levels were 
significantly decreased and 
increased in these age groups, 
respectively (P<0.05). There were 
also significant increases in 
fasting blood glucose and 
triglyceride levels  among 
subjects with and without 
metabolic syndrome in age 
groups 30-34 and 35-40 years old 
(P<0.05). There were decreased 
HDL-cholesterol in age group 30-
34 years old (P<0.05). There were 
no significant differences 
between other parameters in 
subjects with and without 
metabolic syndrome in different 
age groups (P>0.05).  There were 
significant differences in the 
prevalence of metabolic 
syndrome in age groups 20-24 
and 30-34 years old (P<0.05). 
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Table 1. Distribution of metabolic syndrome components according to age group. 
35 - 40 30 - 34 25 - 29 20- 24 Age group (year) 
Parameters 
96.28±12.99 97.95±11.27 90.46±13.47 86.82±13.47 WC (mg/dl) 
 
109.03±75.81 98.87±54.43 92.24±43.36 101.77±85.15 FG (mg/dl) 
 
27.98±5.23 28.36±5.86 25.50±4.95 24.22±4.43 BMI (kg/m2) 
 
115.91±14.97 112.50±18.31 112.33±11.94 107.61±11.38 SBP (mmHg) 
 
70.67±10.90 68.25±13.30 70.80±8.27 67.60±9.82 DBP(mmHg) 
 
111.05±58.89 131.75±75.41 122.0±113.68 97.67±42.52 TG(mg/dl) 
 
45.39±14.0 40.61±10.27 43.98±14.54 43.45±11.88 HDL- chol (mg/dl) 
 
117.45±36.82 119.34±34.85 117.59±49.89 110.42±39.92 LDL- chol (mg/dl) 
 
82(51.25) 20(12.5) 30(18.75) 28(17.50) Total n (%) 
 
  WC: Waist Circumferences, FG: Fasting Glucose, BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, 
TG: triglyceride,  HDL-chol: HDL-cholesterol and LDL-chol: LDL-cholesterol. P>0.05 
 
 
Table 2. Distribution of metabolic syndrome components in subjects with and without metabolic syndrome according to age group 
35 – 40 30 – 34 25 – 29 20 – 24 Age group 
(year) 
 
WMS MS 
 
WMS MS 
 
WMS MS 
 
WMS MS 
 
Parameter 
 
96.62±13.81 
 
94.97±9.41 
 
96.06±13.99 
 
103.14±5.58 
 
86.16±11.22 
 
107.67±5.46* 
 
85.20±8.32 
 
100.33±9.81* 
 
WC 
(mg/dl) 
 
 
91.42±48.48 
 
176.38±116.70* 
 
88.90±19.04 
 
125.0±86.95* 
 
83.02±12.51 
 
129.12±90.25* 
 
84.65±11.31 
 
244.37±249.39* 
 
FG(mg/dl) 
 
 
28.32±5.38 
 
26.66±4.52 
 
28.27±6.81 
 
30.03±4.50 
 
24.15±3.84 
 
30.87±5.57* 
 
23.37±2.79 
 
31.29±9.40* 
BMI 
(kg/m2) 
 
 
117.31±15.23 
 
110.59±12.97 
 
110.62±15.69 
 
118.57±21.93 
 
109.58±11.22 
 
123.33±8.16 
 
105.72±10.41 
 
123.33±5.77 
SBP 
(mmHg) 
 
 
70.84±11.20 
 
70.0±10.0 
 
69.37±11.23 
 
67.85±16.29 
 
71.20±8.95 
 
69.16±4.91 
 
66.92±9.20 
 
73.33±15.27 
DBP 
(mmHg) 
 
 
91.27±39.56 
 
186.65±60.30* 
 
86.0±23.96 
 
212.86±72.60* 
 
71.33±31.57 
 
324.67±93.65* 
 
88.56±33.83 
 
 
173.67±31.26* 
TG(mg/dl) 
 
 
47.36±13.35 
 
37.85±14.27* 
 
45.88±9.51 
 
33.71±7.36* 
 
42.60±10.03 
 
49.50±26.82 
 
45.21±11.19 
 
28.73±51.14* 
HDL- chol 
(mg/dl) 
 
 
117.04±40.07 
 
119.02±20.92 
 
128.55±38.93 
 
111.71±25.86 
 
112.84±46.82 
 
136.65±61.75* 
 
111.56±39.52 
 
100.93±51.19 
LDL- chol 
(mg/dl) 
 
WC: Waist Circumferences, FG: Fasting Glucose, BMI: Body Mass Index, SBP: Systolic Blood Pressure, DBP: Diastolic Blood Pressure, TG: triglyceride, 
HDL-chol: HDL-cholesterol and LDL-chol: LDL-cholesterol. MS: Metabolic Syndrome, WMS: Without Metabolic Syndrome.*P<0.05. 
 
Discussion: 
The results of present study indicated that metabolic syndrome 
components increased as age progresses. Waist circumference and 
HDL-cholesterol (Lower than 50 mg/dl) were increased and 
decreased among different age groups, respectively (Table 1). Many 
studies have revealed that metabolic syndrome is more common in 
women than men[27]. Kazan et al. indicated that the prevalence 
elevated as age increased in 
women than men[28]. Sex seems to 
have an important role in 
elevation of prevalence of risk 
factors like obesity, high lipid 
levels and low HDL cholesterol 
level among females[29]. Our study 
has been shown that Waist 
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circumference and BMI increased form age 25 to 40 years old 
(Table 1). Some other studies have shown that women in different 
age groups indicated higher waist circumference and blood glucose 
and low HDL cholesterol when compared to males[30]. This means 
that sex and age have an important effect on the prevalence of 
cardiovascular risk factors in subjects with metabolic syndrome. 
Study in Turkey showed that the prevalence of metabolic syndrome 
increased from ages 30 to 80 years old[31].  Study of Ford revealed 
that the prevalence was elevated for women among US people aged 
from 20 to 60 years old.  They have shown that there was an 
association between a higher prevalence of metabolic syndrome 
and older age groups[32]. Study of Park et al. indicated that the 
prevalence of the metabolic syndrome increases among women 
from ages 20 to 70 years old[33]. Although age-related differences in 
the mean value of metabolic syndrome components were not 
significant overall in different age groups, but they were significant 
for the components of high fasting glucose, high triglyceride 
(significant in all age groups) and high waist circumference 
(significant in age groups 20-24 and 25-29 years old) among 
women with metabolic syndrome. Our study has been shown that 
Hyperglycemia, hypertriglceridemia, high waist circumference and 
low HDL cholesterol were particularly common amongst the 
woman subjects. The present study indicated that the most 
metabolic syndrome components found in age group 20-24 years 
old (4 components of metabolic syndrome). This means that young 
people is particularly of interest, due to the fact that the risk of 
cardiovascular disease elevates as age progresses.   Study has 
revealed that the causes of metabolic syndrome are associated with 
obesity, lack of physical activity, high LDL-cholesterol diets, aging 
and genetic factors[34].  Studies have shown that low HDL 
cholesterol was seen among females with metabolic syndrome[35-
36]. 
Many studies have revealed that obesity is accompanied with waist 
circumference greater than 88 cm which is a significant prognosis 
for CVD in different age groups[37-39]. It has been shown that 
Obesity, glucose metabolism abnormality, hypertension and 
dyslipidemia are known as a risk factor for CVD leading to fatal 
outcome. These risk factors are the components of metabolic 
syndrome, therefore it is important to determine the components 
of metabolic syndrome to prevent the early onset of CVD [40-42]. 
Study among US women younger than 50 years have been shown 
that the annual death rate from CVD is more than breast cancer[43]. 
In other studies in the United States have indicated that the 
epidemiological increase of overweight and obesity is associated 
with an elevated prevalence of early onset CVD and type 2 diabetes 
mellitus[44-45]. Studies have shown that these epidemic changes may 
in relation with lifestyles alterations[46,47]. Abdominal obesity was 
the common metabolic syndrome component in our study groups 
which is in agreement with other study groups in the United 
States[48]. It has been shown that there is an association between 
the metabolic syndrome and elevation of age and BMI[33,49-50]. Other 
studies have indicated that BMI and age are the most important 
predictors of metabolic syndrome for women and men[48]. Studies 
among different populations 
indicated that waist 
circumference alone[51] or with 
body mass index[52] is a good 
predictors for type 2 diabetes 
mellitus. Report of a WHO Expert 
Committee revealed that waist 
circumference is the most 
effective and easiest 
anthropometric index to be 
utilized for measurement of 
fatness and fat location [53]. Study 
of Ford et al.[38] indicated that 
waist circumference is a better 
predictor than body mass index 
of the metabolic syndrome, 
diabetes, cardiovascular disease. 
There is a relationship between 
abdominal obesity and the 
elevation of portal free fatty acid 
levels which causes 
hyperinsulinemia[54-55]. The 
hyperinsulinemia is associated 
with cardiovascular disease risk 
factors[56]. In our study the mean 
BMI varied from 24.22±4.43 
kg/m2 to 28.36±5.86 kg/m2, 
which is the same to women in 
northeastern Iran, Golestan 
Province (28.6 kg/m2)[57]. Women 
in our study group were 
overweight and obese. The most 
females with metabolic syndrome 
were obese. Obesity is associated 
with the elevation of the risk of 
dyslipidemia, type 2 diabetes 
mellitus and hypertension. 
Obesity is an important predictor 
of coronary heart and 
cardiovascular disease[58].  
Low HDL-cholesterol level is 
associated with increased serum 
triglycerides and remnant 
lipoproteins[59-60]. There are 
association between low HDL 
cholesterol and high LDL-
cholesterol level[61]. Low HDL-
cholesterol level is associated 
with insulin resistance and 
metabolic risk factors[62]. Our 
results indicates that the mean 
value of HDL cholesterol in our 
study group were lower than 50 
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mg/dl. There are contrary relationship between high HDL 
cholesterol and the decreased risk of coronary heart disease [63].  
 
Conclusion: 
High waist circumference, Fasting Glucose and triglyceride, and low 
HDL cholesterol are more effective among subjects with metabolic 
syndrome and, in the presence of obesity may elevate the risk of 
coronary heart disease. The increasing number of overweight and 
obese subjects in our study makes certain that the metabolic 
syndrome begins from young age and will continue as age 
progresses. It seems that women require altering their life style to 
prevent cardiovascular complications. 
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